Last reviewed · How we verify
Vincristin, Daunorubicine, Asparaginase, Methotrexate
Vincristin, Daunorubicine, Asparaginase, Methotrexate is a Small molecule drug developed by Gruppo Italiano Malattie EMatologiche dell'Adulto. It is currently in Phase 1 development.
At a glance
| Generic name | Vincristin, Daunorubicine, Asparaginase, Methotrexate |
|---|---|
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (PHASE2)
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vincristin, Daunorubicine, Asparaginase, Methotrexate CI brief — competitive landscape report
- Vincristin, Daunorubicine, Asparaginase, Methotrexate updates RSS · CI watch RSS
- Gruppo Italiano Malattie EMatologiche dell'Adulto portfolio CI
Frequently asked questions about Vincristin, Daunorubicine, Asparaginase, Methotrexate
What is Vincristin, Daunorubicine, Asparaginase, Methotrexate?
Vincristin, Daunorubicine, Asparaginase, Methotrexate is a Small molecule drug developed by Gruppo Italiano Malattie EMatologiche dell'Adulto.
Who makes Vincristin, Daunorubicine, Asparaginase, Methotrexate?
Vincristin, Daunorubicine, Asparaginase, Methotrexate is developed by Gruppo Italiano Malattie EMatologiche dell'Adulto (see full Gruppo Italiano Malattie EMatologiche dell'Adulto pipeline at /company/gruppo-italiano-malattie-ematologiche-dell-adulto).
What development phase is Vincristin, Daunorubicine, Asparaginase, Methotrexate in?
Vincristin, Daunorubicine, Asparaginase, Methotrexate is in Phase 1.